Related Experiment Videos

Inhibition of murine osteosarcoma cell proliferation by glucocorticoid

Takashi Yamamoto1, Miyuki Nishiguchi, Naokazu Inoue

  • 1Department of Clinical Laboratory, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari, Osaka, 537-0025, Japan.

Anticancer Research
|January 30, 2003
PubMed

Insights

Glucocorticoids (GC) inhibit Dunn Osteosarcoma cell proliferation by inducing apoptosis through the glucocorticoid receptor (GR). This effect was dose-dependent and partially reversible with RU486.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Osteosarcoma (OS) is a primary bone malignancy.
  • Glucocorticoids (GC) are potent regulators of cellular functions.
  • The role of GC in OS proliferation requires further elucidation.

Purpose of the Study:

  • To investigate the in vitro effects of GC on Dunn Osteosarcoma cell proliferation.
  • To characterize the glucocorticoid receptor (GR) in Dunn OS cells.
  • To explore the mechanism underlying GC-induced growth inhibition.

Main Methods:

  • Dunn OS cells were cultured in vitro.
  • Dexamethasone (Dex) and RU486 were used to treat cells.
  • Glucocorticoid receptor (GR) binding assays (Bmax, Kd) were performed.
  • Western blot and immunohistochemistry confirmed GR presence.
  • Apoptosis was assessed via DNA laddering.

Main Results:

  • Dexamethasone (Dex) inhibited Dunn OS cell proliferation in a dose-dependent manner.
  • RU486 partially reversed Dex-induced growth inhibition.
  • Dunn OS cells possess functional GR with Bmax of 19,560 sites/cell and Kd of 5.2 nM.
  • Dex treatment induced apoptosis, evidenced by DNA fragmentation.

Conclusions:

  • Glucocorticoids inhibit Dunn Osteosarcoma cell proliferation via the glucocorticoid receptor.
  • Induction of apoptosis is a key mechanism for GC-mediated growth inhibition in vitro.
  • These findings suggest a potential therapeutic role for GC in Osteosarcoma treatment.

Related Concept Videos